Related Experiment Videos
Anti-proliferative activity and mechanism of action of titanocene dichloride
C V Christodoulou1, A G Eliopoulos, L S Young
1CRC Institute for Cancer Studies, The University of Birmingham Medical School, UK.
Abstract:
Development of resistance to cytotoxic agents is a major limitation to their clinical use. Novel compounds are synthesized with a view to develop non-cross-resistant, less toxic and more potent activity. The detection of the anti-tumour properties of the inorganic compound cisplatin stimulated a broad search for other metal-containing complexes. Titanocene dichloride was synthesized on this basis and has shown potent anti-neoplastic activity in experimental animals. We have examined the in vitro activity of titanocene dichloride in two pairs of platinum-sensitive and resistant human ovarian carcinoma cell lines, A2780/2780CP and CH1/CH1cisR, and in mutated p53- and bcl-2-transfected clones of A2780 cells. A time- and concentration-dependent anti-proliferative effect was observed in all cell lines treated with titanocene dichloride. The drug was found to significantly overcome platinum resistance in the 2780CP and the CH1 cisR cell lines and in the bcl-2 and the mutant p53 transfectants of A2780 cells. Titanocene dichloride induced a block in late S/early G2 phase of the cell cycle; however apoptotic cell death occurred from any phase of cycle. Titanium-DNA adducts were detected in A2780 cells treated with titanocene dichloride using atomic absorption spectrometry, suggesting that DNA may be a target for this drug. In agreement with this finding, p53 accumulated rapidly in drug-treated A2780 cells, indicative of a role for titanocene dichloride as a DNA-damaging agent. We have also performed studies to determine whether titanocene dichloride could demonstrate synergy with other cytotoxic agents in vitro. Isobologram analysis of cytotoxicity data obtained suggests that the combination of titanocene dichloride and 5-fluorouracil (5-FU) is synergistic. The potent in vivo anti-tumour activity of this compound, supported by the encouraging results from two phase I clinical trials, suggests that titanocene dichloride could be a promising novel chemotherapeutic agent.
Insights
Titanocene dichloride effectively combats platinum-resistant ovarian cancer by targeting DNA and overcoming resistance mechanisms. This novel compound shows synergistic effects with 5-fluorouracil, indicating its potential as a promising chemotherapeutic agent.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- Cytotoxic agent resistance limits cancer treatment efficacy.
- Metal-containing complexes, like cisplatin, show anti-tumour properties.
- Titanocene dichloride (TD) emerged as a novel compound with potent anti-neoplastic activity in preclinical models.
Purpose of the Study:
- To evaluate the in vitro anti-cancer activity of titanocene dichloride (TD) against platinum-sensitive and resistant human ovarian carcinoma cell lines.
- To investigate TD's ability to overcome platinum resistance and its effects on cell cycle and apoptosis.
- To explore potential synergistic interactions between TD and 5-fluorouracil (5-FU).
Main Methods:
- In vitro testing of TD on human ovarian carcinoma cell lines (A2780/2780CP, CH1/CH1cisR) and transfected clones.
- Cell cycle analysis and detection of titanium-DNA adducts via atomic absorption spectrometry.
- Isobologram analysis to assess drug synergy with 5-fluorouracil.
Main Results:
- TD demonstrated time- and concentration-dependent anti-proliferative effects across all tested cell lines.
- TD significantly overcame platinum resistance in resistant cell lines and mutant p53/bcl-2 transfectants.
- Titanium-DNA adducts and p53 accumulation indicated DNA damage; synergistic activity observed with 5-FU.
Conclusions:
- Titanocene dichloride exhibits potent anti-cancer activity and overcomes platinum resistance in ovarian cancer models.
- TD functions as a DNA-damaging agent, inducing cell cycle arrest and apoptosis.
- The synergistic combination of titanocene dichloride and 5-fluorouracil warrants further investigation for clinical application.